Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.13
0.00 (0.00%)
Mar 16, 2026, 4:00 PM EDT - Market open
Lyell Immunopharma Revenue
In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%. Lyell Immunopharma had revenue of $6.00K in the quarter ending December 31, 2025, a decrease of -45.45%.
Revenue (ttm)
$36.00K
Revenue Growth
-40.98%
P/S Ratio
13,680.00
Revenue / Employee
$120
Employees
300
Market Cap
492.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| Fulcrum Therapeutics | 80.00M |
| Invivyd | 53.43M |
| Verastem | 30.91M |
| Entrada Therapeutics | 25.42M |
| Prothena Corporation | 9.68M |
LYEL News
- 4 days ago - Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - GlobeNewsWire
- 8 days ago - Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - GlobeNewsWire
- 10 days ago - Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 22 days ago - Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data - Seeking Alpha
- 3 months ago - Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire